Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue - a GC-TOFMS based metabolomics studyVisa övriga samt affilieringar
2012 (Engelska)Ingår i: BMC Genomics, E-ISSN 1471-2164, Vol. 13, nr 1, artikel-id 334Artikel i tidskrift (Refereegranskat) Published
Abstract [en]
BACKGROUND: Changes in energy metabolism of the cells are common to many kinds of tumors and are considered a hallmark of cancer. Gas chromatography followed by time-of-flight mass spectrometry (GC-TOFMS) is a well-suited technique to investigate the small molecules in the central metabolic pathways. However, the metabolic changes between invasive carcinoma and normal breast tissues were not investigated in a large cohort of breast cancer samples so far.
RESULTS: A cohort of 271 breast cancer and 98 normal tissue samples was investigated using GC-TOFMS-based metabolomics. A total number of 468 metabolite peaks could be detected; out of these 368 (79%) were significantly changed between cancer and normal tissues (p<0.05 in training and validation set). Furthermore, 13 tumor and 7 normal tissue markers were identified that separated cancer from normal tissues with a sensitivity and a specificity of >80%. Two-metabolite classifiers, constructed as ratios of the tumor and normal tissues markers, separated cancer from normal tissues with high sensitivity and specificity. Specifically, the cytidine-5-monophosphate / pentadecanoic acid metabolic ratio was the most significant discriminator between cancer and normal tissues and allowed detection of cancer with a sensitivity of 94.8% and a specificity of 93.9%.
CONCLUSIONS: For the first time, a comprehensive metabolic map of breast cancer was constructed by GC-TOF analysis of a large cohort of breast cancer and normal tissues. Furthermore, our results demonstrate that spectrometry-based approaches have the potential to contribute to the analysis of biopsies or clinical tissue samples complementary to histopathology.
Ort, förlag, år, upplaga, sidor
2012. Vol. 13, nr 1, artikel-id 334
Nationell ämneskategori
Medicinsk bioteknologi (med inriktning mot cellbiologi (inklusive stamcellsbiologi), molekylärbiologi, mikrobiologi, biokemi eller biofarmaci) Cancer och onkologi
Identifikatorer
URN: urn:nbn:se:oru:diva-63667DOI: 10.1186/1471-2164-13-334ISI: 000308085800001PubMedID: 22823888Scopus ID: 2-s2.0-84865602043OAI: oai:DiVA.org:oru-63667DiVA, id: diva2:1169230
Forskningsfinansiär
EU, FP7, Sjunde ramprogrammet, 200327 2576692017-12-222017-12-222024-01-17Bibliografiskt granskad